Currently, CAR T cells specific for CD19 have been FDA-approved for the treatment of various B cell malignancies such as large B cell lymphoma or acute lymphoblastic leukemia (ALL) 37, 38, while BCMA CAR T cells were recently approved for the treatment of multiple myeloma 39. Here, CD19 is linked to acute lymphoblastic leukemia.